Xerion Limited is an Australian-based consumer healthcare company focused on revolutionizing standard of care in dermatology through the development and commercialization of innovative therapies and diagnostics. Our nailKALM products are currently sold through pharmacies, podiatrists and online at nailKALM.com
Xerion Limited also has the exclusive commercial license to the PUFAcoatTM technology developed by Professor Robert Gibson and Dr Ge Liu of the School of Agriculture, Food and Wine, University of Adelaide, which has the ability to transform certain aspects of the personalised nutrition market. The technology allows simple, accessible, personalized determination of an individual’s fatty acid profile to help improve their health and achieve their wellness goals. One application for this technology is its utility as a companion diagnostic tool for the high value consumer supplement market for which we have a distribution agreement with BASF, a global leader in fish oil production.
The company’s product portfolio includes proprietary algae bioactives and TGA approved anti-fungal products:
- AMYCOT®: algal complex mix of bioactives with anti-fungal, anti-bacterial, anti-inflammatory and skin-repair properties.
- KALM: Xerion’s lead product, a topical anti-fungal product line.
- SKINACTIVÉ®: Xerion’s proprietary anti-aging and skin care cosmetic range.
- PUFAcoat: a proprietary dried blood spot (DBS) which stabilises fatty acids for long periods of time in ambient conditions facilitating the accurate measurement of fatty acids and is a useful tool in determining the Omega 3 Index.
Xerion has a robust product pipeline and research partnerships to extend its product range and indications.